在胰腺瘤发生过程中,分子动力学推动了KRAS突变体之间的表型差异
bioRxiv : the preprint server for biology
|June 12, 2025
概括
不同的KRAS突变启动了不同的胰腺癌轨迹. 克拉斯G12D驱动瘤启动,而克拉斯G12R/V显示持续瘤生长的缺陷由于信号通路变化.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 胰腺癌 (PDAC) 的发展包括由炎症驱动的acinar-to-ductal metaplasia (ADM).
- 突变KRAS是PDAC的关键驱动因素,但具体KRAS突变如何影响细胞命运和瘤启动尚不清楚.
研究的目的:
- 在胰腺癌中研究由不同KRAS变异驱动的突变特异性血统逆转和瘤启动.
- 了解KRAS基因突变依赖的瘤性轨迹背后的分子机制.
主要方法:
- 使用了新的Ptf1a-Td番茄小鼠来追踪血统变化.
- 在体内各种遗传学,药理学和炎症性干扰下使用多个KRAS突变 (G12D,G12R,G12V).
- 分析了EGFR,Rac1/Vav1和Akt信号通路.
主要成果:
- 克拉斯G12D促进了血统逆转,增强器重编程和瘤启动.
- 克拉斯G12R/V突变引发瘤,但未能维持脱差和瘤程序.
- 在KRAS G12R/V中的缺陷涉及EGFR信号和Rac1/Vav1激活受损,尽管构成性Akt激活可以拯救瘤发生.
结论:
- 在KRAS G12D,G12V和G12R之间存在一个层次结构,可以驱动胰腺瘤的发病.
- 对EGFR,PI3K/AKT和RAC1信号通路的异质激活决定了突变特异性的致癌途径.
- 了解这些独特的KRAS驱动的途径对于开发PDAC的等位基因特异性治疗策略至关重要.
相关概念视频
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancers Originate from Somatic Mutations in a Single Cell
11.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.8K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


